An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
VANCOUVER, British Columbia--(BUSINESS WIRE)--
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).
A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’
